These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17047115)

  • 1. A pilot study in patients with established advanced liver fibrosis using pirfenidone.
    Armendáriz-Borunda J; Islas-Carbajal MC; Meza-García E; Rincón AR; Lucano S; Sandoval AS; Salazar A; Berumen J; Alvarez A; Covarrubias A; Aréchiga G; García L
    Gut; 2006 Nov; 55(11):1663-5. PubMed ID: 17047115
    [No Abstract]   [Full Text] [Related]  

  • 2. Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.
    Grizzi F
    Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):961-2. PubMed ID: 19650793
    [No Abstract]   [Full Text] [Related]  

  • 3. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.
    Zhao XY; Zeng X; Li XM; Wang TL; Wang BE
    Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):963-8. PubMed ID: 19413596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans.
    Pesce E; Struma E; Giri SN; Margolin SB
    Res Commun Mol Pathol Pharmacol; 2004; 115-116():39-48. PubMed ID: 17564304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.
    Fontana RJ; Sanyal AJ; Mehta S; Doherty MC; Neuschwander-Tetri BA; Everson GT; Kahn JA; Malet PF; Sheikh MY; Chung RT; Ghany MG; Gretch DR;
    Am J Gastroenterol; 2006 May; 101(5):983-92. PubMed ID: 16573786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
    Dosanjh A
    Eur J Pharmacol; 2006 May; 536(3):219-22. PubMed ID: 16581063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in treating liver fibrosis.
    Poo JL; Muñoz LE
    Ann Hepatol; 2014; 13(6):845-6. PubMed ID: 25332275
    [No Abstract]   [Full Text] [Related]  

  • 8. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.
    Dosanjh A
    Transplant Proc; 2007 Sep; 39(7):2153-6. PubMed ID: 17889122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical decisions in hepatology: the pirfenidone case analysis.
    Chavez-Tapia NC; Méndez-Sánchez N
    Ann Hepatol; 2014; 13(2):163-5. PubMed ID: 24552857
    [No Abstract]   [Full Text] [Related]  

  • 10. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.
    Loeh B; Drakopanagiotakis F; Bandelli GP; von der Beck D; Tello S; Cordani E; Rizza E; Barrocu L; Markart P; Seeger W; Guenther A; Albera C
    Am J Respir Crit Care Med; 2015 Jan; 191(1):110-3. PubMed ID: 25551350
    [No Abstract]   [Full Text] [Related]  

  • 11. Idiopathic pulmonary fibrosis and pirfenidone.
    Collard HR
    Eur Respir J; 2010 Apr; 35(4):728-9. PubMed ID: 20356985
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.
    Levitt J; Gould MK
    Am J Respir Crit Care Med; 2005 Nov; 172(9):1228-9; author reply 1229. PubMed ID: 16249322
    [No Abstract]   [Full Text] [Related]  

  • 14. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 15. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005; 37(1):130-3. PubMed ID: 15808571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone and chronic progressive obliterative airway disease.
    Dosanjh A
    J Heart Lung Transplant; 2006 Apr; 25(4):490. PubMed ID: 16563985
    [No Abstract]   [Full Text] [Related]  

  • 18. The questionable efficacy of pirfenidone in IPF.
    Mathai SC; Polito AJ
    Am J Respir Crit Care Med; 2005 Nov; 172(9):1228. PubMed ID: 16249323
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a double-blind and acute and chronic lameness of musculoskeletal origin in an open multi-centered field trial in horses.
    Giri SN; Margolin SB
    Res Commun Mol Pathol Pharmacol; 2005; 117-118():47-63. PubMed ID: 18426078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.
    Gosselin LE; Williams JE; Personius K; Farkas GA
    Muscle Nerve; 2007 Feb; 35(2):208-16. PubMed ID: 17058274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.